Krystal Biotech to Present at Upcoming Investor Conferences

KRYS 11.27.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Citi’s 2024 Global Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:7th Annual Evercore HealthCONx Conference
Full Press ReleaseSEC FilingsOur KRYS Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
  • 12.18.2024 - Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
  • 12.12.2024 - KB408 and KB407 Interim Clinical Update

Recent Filings

  • 12.18.2024 - 8-K Current report
  • 12.18.2024 - EX-99.1 EX-99.1
  • 12.13.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

PITTSBURGH,Nov. 27, 2024(GLOBE NEWSWIRE) --Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced thatKrish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:

  • Citi’s 2024 Global Healthcare Conference onDecember 3, 2024inMiami, Florida; fireside chat scheduled for8:45 am ET
  • 7th AnnualEvercore HealthCONx ConferenceonDecember 4, 2024inCoral Gables, Florida; fireside chat scheduled for2:10 pm ET

Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company’swebsite. Archived versions of the webcasts will also be available on the Investors section of the Company’s website for at least 30 days.

AboutKrystal Biotech, Inc.

Krystal Biotech, Inc.(NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics.Krystal Biotechis headquartered inPittsburgh, Pennsylvania. For more information, please visithttp://www.krystalbio.com, and follow @KrystalBiotech onLinkedInandX(formerly Twitter).

CONTACTInvestors and Media:Stéphane PaquetteKrystal Biotechspaquette@krystalbio.com

Primary Logo

Source: Krystal Biotech, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com